- Home
- DDS vs RNA Comparison
DDS vs RNA Comparison
Compare DDS & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DDS | RNA |
|---|---|---|
| Founded | 1938 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 2.3B |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | DDS | RNA |
|---|---|---|
| Price | $585.93 | $14.97 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 3 | 20 |
| Target Price | ★ $519.67 | $69.26 |
| AVG Volume (30 Days) | 141.6K | ★ 2.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.06 | $88.12 |
| Revenue Next Year | $2.02 | $18.11 |
| P/E Ratio | $18.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $282.24 | $13.06 |
| 52 Week High | $741.98 | $73.06 |
Technical Indicators
Market Signals| Indicator | DDS | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 39.13 | 4.22 |
| Support Level | $589.36 | $13.06 |
| Resistance Level | $632.43 | $72.52 |
| Average True Range (ATR) | 29.62 | 0.83 |
| MACD | -3.14 | -6.15 |
| Stochastic Oscillator | 13.31 | 3.11 |
Price Performance
Historical ComparisonAbout DDS Dillard's Inc.
Dillard's Inc is an American fashion apparel, cosmetics, and home furnishings retailer. Its stores offer a large variety of merchandise and feature products from both national and exclusive brand sources. The company also operates a general contracting construction company, CDI Contractors. CDI Contractors' business includes constructing and remodelling stores for Dillards. The merchandise selections include exclusive brand merchandise such as Antonio Melani, Gianni Bini, Daniel Cremieux, Roundtree & Yorke, and private-label merchandise, among others. The company operates in two business segments; Retail Operations and Construction. The Retail Operations segment generates maximum revenue for the company.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. The company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.